期刊文献+

丙戊酸钠代谢产物2-ene-VPA RP-HPLC分析方法的建立 被引量:3

Establishment of RP-HPLC method of sodium valproate metabolite 2-ene-VPA in plasma
原文传递
导出
摘要 目的:建立癫痫患者血浆中丙戊酸钠(VPA)代谢产物2-丙基-2-戊烯酸(2-ene-VPA)的HPLC测定方法。方法:血浆用乙酸乙酯提取,以2,4’-二溴苯乙酮作为内标,氮气挥干样品,色谱柱:ZORBAX SB-C18柱(4.6 mm×150 mm,5μm);流动相:甲醇-水(55∶45);检测波长:217 nm;流速:1.0ml·min^-1;柱温:35℃;进样温度:20℃。结果:内标2,4’-二溴苯乙酮和2-ene-VPA的保留时间分别为11.2 min和5.1 min,2-ene-VPA的血浆浓度在0.5-16.0μg·ml^-1范围内,2-ene-VPA与内标2,4’-二溴苯乙酮的峰面积比与浓度呈良好的线性关系(R〉0.999),平均回收率为(96.85±0.33)%,日内RSD〈5%,日间RSD〈5%。结论:本法经济、快速、简便,适用于临床上2-ene-VPA的测定及研究。 OBJECTIVE To establish a rapid analysis method for determination of sodium valproate metabolite 2-ene-VPA in plasma by RP-HPLC.METHODS Plasma sample was extracted with ethyl acetate,2,4'-dibromoacetophenone as an internal standard.Nitrogen gas was used to dry samples under the following conditions:UV detector(217 nm)and ZORBAX SB-C18column(150 mm×4.6 mm,5μm);mobile phase consisted of methanol-water(55∶45);flow rate 1.0ml·min^-1;column temperature 35 ℃.RESULTS Retention times of 2-ene-VPA and internal standard were 5.1 min and 11.2 min,respectively.Linear range was 0.5-16μg·ml^-1.Average recovery rate was(96.85±0.33)%.Inter-day and intra-day relative standard deviation(RSD)was all less than 5%.CONCLUSION This method is economic,rapid,convenient and suitable for clinical routine monitoring and research of 2-ene-VPA.
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2015年第18期1654-1658,共5页 Chinese Journal of Hospital Pharmacy
基金 贵州省卫生厅基金(编号:gzwkj2010-1-003)
关键词 2-丙基-2-戊烯酸 丙戊酸钠代谢产物 RP-HPLC 2-ene-VPA metabolites of sodium valproate HPLC
  • 相关文献

参考文献17

  • 1Jayakumar S, Thomas KH. Assessment of the role of in situ Generated (E)-2,4 diene-valp- roic acid in the toxicity of valp- roic acid and (E)-2-ene-valproic acid in sandwich-cultured rat hepatocytes[J]. Toxicology and Applied Pharmacology, 2012, 264(3) : 413-422.
  • 2储小曼,郭岑,张丽芳.丙戊酸的代谢特征与其肝毒性的相关性[J].中国医院药学杂志,2013,33(19):1611-1614. 被引量:23
  • 3Dupuis RE, Lichtman SN, Pollack GM. Acute valproic acid o- verdose: Clinical course and pharmacokinetic disposition of val- proic acid and Metabolites[J]. Drug Safety, 1990,5 ( 1 ) : 65-71.
  • 4Lewis C, Deshpande A, Tesar GE,et al. Valproate-induced hy- perammonemic encephaloly athy: a brief review[J]. Curr Med Res Opin, 2012,28(6) : 1039-1042.
  • 5Christie M, Mock H, Kristen H. Levocarnitine for valproic- acid induced hyperammonemic encephalopathy [J]. Am J Health Syst Pharm, 2012, 69(1):35-39.
  • 6Lheureux PE, Hantson P. Carnitine in the treatment of valp- roic aci&induced toxicity [J]. Clinical Toxicology, 2009, 47 (2):101-111.
  • 7Andrew S, Davison, Anna M, et al. The Consequences of Valproate Overdose[J]. Clinical Chemistry,2011,57(9):1233- 1238.
  • 8Gram L, Flachs H, Parnas J, et al. Sodium Valproate, Plasma Level and Clinical Effect in Epilepsy: A Controlled Study[J]. Epilepsia, 1979,20(3) : 303-311.
  • 9Kiang TK, Teng XW, Karagiozov S, et al. Role of Oxidative Metabolism in the Effect of Valproic Acid on Markers of Cell Viability, Necrosis, and Oxidative Stress in Sandwich- Cul- tured Rat Hepatocytes[J]. Toxicological Sciences, 2010, 118 (2) :501-509.
  • 10Amini-Shirazi N, Ahmadkhaniha R, Shadnia S, et al. Deter- mination of VPA and its Two Important Metabolites in Iranian Overdosed Patients[J]. International Journal of Pharm-acolo gy, 2010,6(6) : 854-862.

二级参考文献42

  • 1童光磊,李宇清,鲍劲松,李司南,周陶成.丙戊酸钠治疗儿童癫痫的血药浓度监测结果分析[J].中国药物与临床,2007,7(3):230-231. 被引量:4
  • 2Loscher W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy [J]. CNS Drugs, 2002, 16(10): 669-694.
  • 3Rogawski MA. Loscher W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions [J]. Nat Med, 2004, 10(7) :685 692.
  • 4Abbott Laboratories (2007). Clinical Pharmacology of Dival proex, Abbott Laboratories Inc., USA: http://www, rxab bott. eom/pdf/depakote.
  • 5Nagai G, 0no S, Yasui Furukori N, et al. Formulations of valproate alter valproate metabolism: a single oral dose kinetic study [J]. Ther Drug Monit, 2009, 31 (5) :592-596.
  • 6Garikipati V, Toops DS, Fang Q. Bioequivalenee studies of a new valproic acid delayed-release capsule and divalproex sodium delayed-release tablet [J]. Curt Med Res 0pin, 2008, 24(7): 1869-1876.
  • 7Garnett WR, Anderson GD, Collins RJ. Antiepileptie drugs// Applied pharnmcokinetie ~>. pharmaeodynamcis[M]. Principles of drug therapeutic monitoring. 4th ed. Philadelphia: I.ippin- cott Williams ~- wilkins,2006:491 511.
  • 8Silva MF, Aires CC, Luis PB, et al. Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review [J]. J Inherit Metab Dis, 2008, 31(2):2f15 216.
  • 9Lampon N, Tutor JC. Apparent clearance of valproic acid in elderly epileptic patients: estimation of the confounding effect of albumin concentration [J]. Ups J Med Sci, 2012, 117(1): 41 46.
  • 10Abbott FS, Anari MR. Chemistry and biotransformation// Milestones in drug therapy-valproate[M]. Basel: Birkhauser Verlag, 1999: 47-75.

共引文献22

同被引文献32

  • 1Ghodke-Puranik Y, Thom CF, Lamba JK,eZ al. Valproic acidpathway: pharmacokinetics and pharmacodynamics [J]. Phar-macog Genom,2013,23(4): 236-241.
  • 2Amini-Shirazi N,Ahmadkhaniha R,Shadnia al. Determi-nation of VP A and its two important metabolites in iranian o-verdosed patients[J]. Inter J Pharmacol, 2010,6(6) :854-862.
  • 3Dupuis RE’Lichtman SN, Pollack GM. Acute valproic acid o-verdose : Clinical course and pharmacokinetic disposition of val-proic acid and Metabolites [J〕. Drug Saf,1990,5(1): 65-71.
  • 4Loscher W,Nau Htetal. Valproic acid; metabolite concentra-tions in plasma and brain,antic- onvulsant activity and effectson GABA metabolism during subacute treatment in mice[J].Arch Int Pharmacodyn Ther,1982,257(1) :20-31.
  • 5Andrew S, Davison, Anna M, etal. The consequences of val-proate overdose [J]. Clinical Chemistry, 2011,57(9): 1233-1238.
  • 6Mock CM, Schwetschenau KH. Levocarnitine for valproicacid-induced hyperammonemic encephalopathy [ J ]. Am JHealth Syst Pharm, 2012,69(21) : 35-39.
  • 7Lewis C,Deshpande A, Tesar GE,et al. Valproate-inducedhyperainnionemic encephalopathy : a brief review[J]. Curr MedResOpin,2012,28(6); 1039-1042.
  • 8Otoul C, De Smedt H, Stockis A. Lack of pharmacokinetic in-teraction of LEV on carbamazepine,valproic acid, topiramate,and lamotrigine in children with epilepsy[J]. Epilepsia, 2007,48(11):2111-2115.
  • 9Roh SY, Jang HS, Jeong EH, et al. Valproic acid-induced hy-perammonemic encephalopathy promoted by levetiracetam [J].J Epilepsy Res, 2014,4(2) :82-84.
  • 10Jayakumar S, Thomas KH. Assessment of the role of in situGenerated (E)-2,4 diene-valproic acid in the toxicity of valpro-ic acid and (E )-2-ene-valproic acid in sandwich-cultured rathepatocytes[J]. Toxicol Appl Pharmacol, 2012, 264 (3) : 413-422.

引证文献3

二级引证文献61

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部